Global Anti-Tuberculosis Therapeutics Market, By Disease Type (Active TB, Latent TB, Others), Treatment Type (First-Line of Drugs, Second-Line of Drugs, Others), Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Capsules, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the anti-tuberculosis therapeutics market is anticipated to grow rapidly during the forecast period. Approximately 1.5 million people died from tuberculosis (TB), as per the WHO's Global Tuberculosis (TB) Report 2020. Tuberculosis is one of the top ten causes of death worldwide, and the leading cause of death caused by a single infectious agent. Overall, the global incidence of tuberculosis and multidrug-resistant tuberculosis poses a challenge to leading medical regulatory bodies. The significant involvement of both the medical community and the government in combating tuberculosis is predicted to lead to a rise in the number of tuberculosis diagnosis. Thus, this lead to the high demand for anti-tuberculosis therapeutics market.
Data Bridge Market Research analyses that the anti-tuberculosis therapeutics market was valued at USD 1266.27 million in 2021 and is expected to reach USD 2127.36 million by 2029, registering a CAGR of 6.70% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Tuberculosis (TB) is a contagious infection that generally infects the lungs. This illness can also spread to other body parts such as spine and brain. Mycobacterium tuberculosis is a form of bacteria which causes it. Drug companies are concentrating their efforts on creating medications that can reduce the length of treatment and help overcome the hurdles of drug-susceptible and drug-resistant tuberculosis. There are two forms of tuberculosis treatment: first-line treatment, second-line treatment, and drug-resistant treatment.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Active TB, Latent TB, Others), Treatment Type (First-Line of Drugs, Second-Line of Drugs, Others), Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Capsules, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
AstraZeneca (UK), Johnson & Johnson Private Limited (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Allergan (Ireland), Merck & Co., Inc. (US), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Hikma Pharmaceuticals PLC (UK), Cipla Inc. (US), Lannett (US), Fresenius Kabi AG (Germany), Endo International plc (Ireland), Otsuka Pharmaceutical Co., Ltd. (Japan), STI Pharma, LLC (US), Macleods Pharmaceuticals Ltd. (India)
|
|
Market Opportunities
|
|
Anti-Tuberculosis Therapeutics Market Dynamics
Drivers
- Rise in the prevalence of tuberculosis
The rising prevalence of tuberculosis is a major factor driving the anti-tuberculosis therapeutics market's growth rate. According to in 2020, approximately 10 million people fell ill with tuberculosis globally. 3.3 million were women, 5.6 million were men, and 1.1 million were children. The transmission of tuberculosis (TB) occur from person to person through the air. People with lung TB spread the TB germs into the air when they cough, sneeze, or spit. A person become infected by inhaling few of these germs.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of anti-tuberculosis therapeutics market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing number of geriatric population
The rising geriatric population is expected to enhance the growth rate of anti-tuberculosis therapeutics market. Geriatric people are more prone to chronic and acute diseases due to the weak immune system. Various conditions such as diabetes, HIVAIDS, kidney diseases and others are the major factors that will weak the immune system. Along with this, certain medication, including chemotherapy, drugs used to treat Crohn's disease, rheumatoid arthritis, and psoriasis, will increase the risk of tuberculosis as these can weaken the immune system.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the anti-tuberculosis therapeutics market. Additionally, changing lifestyle of people and rising incidences of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) cases in developing countries will result in the expansion of anti-tuberculosis therapeutics market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the anti-tuberculosis therapeutics market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. The advent of new and more efficient diabetic treatment and monitoring products is estimated to boost the market's growth rate in the future.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the anti-tuberculosis therapeutics market during the forecast period.
Restraints/Challenges
On the other hand, the high cost of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) drugs will obstruct the market's growth rate. Developing economies' lack of healthcare infrastructure and product recalls will challenge the anti-tuberculosis therapeutics market. Additionally, side effects linked with anti-tuberculosis drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This anti-tuberculosis therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anti-tuberculosis therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Anti-tuberculosis therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Anti-Tuberculosis Therapeutics Market
Over the projected period, the anti-tuberculosis therapeutics market is expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations have imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world are having difficulty continuing their supply chain activities. The supply chain slowness has also hampered the anti-tuberculosis therapeutics market.
Global Anti-Tuberculosis Therapeutics Market Scope
The anti-tuberculosis therapeutics market is segmented on the basis of diseases type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Active TB
- Latent TB
- Others
Treatment Type
- First-Line of Drugs
- Isoniazid
- Ethambutol
- Rifampin
- Others
- Second-Line of Drugs
- Thiacetazone
- Paraaminosalicyclic Acid (PAS)
- Others
- Others
Diagnosis
- Blood Tests
- Imaging Tests
- Chest X-ray
- CT scan
- Sputum Tests
- Others
Dosage form
- Tablets
- Capsules
- Injections
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Anti-Tuberculosis Therapeutics Market Regional Analysis/Insights
The anti-tuberculosis therapeutics market is analysed and market size insights and trends are provided by country, diseases type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Anti-tuberculosis therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the anti-tuberculosis therapeutics market because of the growing number of research and development activities and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, increasing adoption of Bacillus Calmette–Guérin (BCG) vaccine will further influence the market's growth rate in this region
Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers in this region. Also, development of healthcare infrastructure and increasing government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Anti-Tuberculosis Therapeutics Market Share Analysis
The Anti-tuberculosis therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anti-tuberculosis therapeutics market.
Some of the major players operating in the anti-tuberculosis therapeutics market are:
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Eli Lilly and Company (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Allergan (Ireland)
- Merck & Co., Inc. (US)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Hikma Pharmaceuticals PLC (UK)
- Cipla Inc. (US)
- Lannett (US)
- Fresenius Kabi AG (Germany)
- Endo International plc (Ireland)
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- STI Pharma, LLC (US)
- Macleods Pharmaceuticals Ltd. (India)
SKU-